Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs
Isomorphic Labs, the brainchild of Nobel Laureate Demis Hassabis, has an ambitious mission even by the standards of AI labs: curing cancer.
Isomorphic Labs, a Google DeepMind spinoff led by AI pioneer Demis Hassabis, aims to revolutionize drug design using artificial intelligence. President Max Jaderberg believes that within five years, all drugs will be designed by AI. The company has made significant progress thanks to AlphaFold, an AI model developed by DeepMind, which won Hassabis a Nobel Prize and transformed protein mapping.
Jaderberg claims that Isomorphic plans to use its AI models to predict how drug molecules will interact with every other molecule in the body, reducing trial-and-error and minimizing adverse side effects. The company is focused on developing breakthrough drugs for cancer, immune system conditions, and inflammatory diseases. Isomorphic has formed research partnerships with major pharmaceutical companies, and the AI-designed drug design engine has enabled preclinical testing with human trials on the horizon.
Despite the daunting challenges, Isomorphic remains steadfast in its mission to make disease a thing of the past.
Written by urgent.news from Business Insider's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
